Shots:
- Pulnovo Medical secured an oversubscribed $100M financing round led by Medtronic, with existing participation from EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures
- The Pulnovo Medical and Medtronic also entered a strategic commercial agreement to explore future global commercialization opportunities leveraging the commercial synergy between Pulnovo and Medtronic, along with Medtronic’s distinctive and far-reaching global commercialization capabilities
- Funds will support clinical development, regulatory strategies, and commercialization of Pulnovo’s PADN system, which holds US FDA Breakthrough Device designation and is under IDE study in the US
Ref: PR Newswire | Image: Pulnovo Medical | Press Release
Related News: Medtronic to Acquire Scientia Vascular for $550M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
